Nephrocare Health Services Credit Rating Upgraded to IND AA-

Long-term bank loan facilities upgraded to IND AA-/Stable; company achieves net cash position in FY26.

Reader Takeaway: Improved balance sheet health bolsters confidence, but monitor working capital cycles and international market execution risks.

What just happened

India Ratings and Research (Ind-Ra) has upgraded the long-term bank loan rating for Nephrocare Health Services to 'IND AA-/Stable' from 'IND A+/Positive'. The short-term credit rating was affirmed at 'IND A1+'. This rating action signals a significant improvement in the company's creditworthiness and overall financial stability.

Why this matters

A credit rating upgrade from a premier agency typically lowers borrowing costs and enhances investor sentiment. The transition to a net cash position—driven by an equity raise in December 2025—demonstrates management's ability to deleverage effectively while scaling the business.

Financial Performance

Nephrocare reported strong growth in FY26, with consolidated revenue reaching Rs 1,000 crore, up from Rs 760 crore in FY25. Operating efficiency also improved, with EBITDA margins expanding to 22.7% compared to 22.0% in the previous fiscal year. Debt repayment has been aggressive, with the company clearing all India-level term loans by the end of FY26.

Risks to watch

Despite the positive rating, the company faces structural challenges:

• Working Capital: A high debtor period of 116 days highlights the capital-intensive nature of the dialysis business.
• International Exposure: With 42% of revenue coming from international markets, the company remains sensitive to geopolitical shifts and currency volatility.
• Execution: Aggressive expansion plans introduce inherent ramp-up risks in new territories.

Context metrics (FY26)

• Revenue: Rs 1,000 crore
• EBITDA: Rs 230 crore
• Cash & Equivalents: Rs 430 crore
• Debtor Days: 116 days